Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

We analyzed 21 children with leukemia receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from killer immunoglobulin (Ig)-like receptors (KIR) ligand-mismatched donors. We showed that, in most transplantation patients, variable proportions of donor-derived alloreactive natural killer (NK) cells displaying anti-leukemia activity were generated and maintained even late after transplantation. This was assessed through analysis of donor KIR genotype, as well as through phenotypic and functional analyses of NK cells, both at the polyclonal and clonal level. Donor-derived KIR2DL1(+) NK cells isolated from the recipient displayed the expected capability of selectively killing C1/C1 target cells, including patient leukemia blasts. Differently, KIR2DL2/3(+) NK cells displayed poor alloreactivity against leukemia cells carrying human leukocyte antigen (HLA) alleles belonging to C2 group. Unexpectedly, this was due to recognition of C2 by KIR2DL2/3, as revealed by receptor blocking experiments and by binding assays of soluble KIR to HLA-C transfectants. Remarkably, however, C2/C2 leukemia blasts were killed by KIR2DL2/3(+) (or by NKG2A(+)) NK cells that coexpressed KIR2DS1. This could be explained by the ability of KIR2DS1 to directly recognize C2 on leukemia cells. A role of the KIR2DS2 activating receptor in leukemia cell lysis could not be demonstrated. Altogether, these results may have important clinical implications for the selection of optimal donors for haplo-HSCT.

[1]  F. Christiansen,et al.  KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. , 2008, International immunology.

[2]  P. Parham,et al.  Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL31 , 2008, The Journal of Immunology.

[3]  J. Chewning,et al.  KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro1 , 2007, The Journal of Immunology.

[4]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[5]  Des C. Jones,et al.  Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies , 2007, European journal of immunology.

[6]  P. Parham,et al.  Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells1 , 2007, The Journal of Immunology.

[7]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[8]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[9]  M. Carrington.  Faculty Opinions recommendation of Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. , 2006 .

[10]  Eric Vivier,et al.  Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Lybarger,et al.  Licensing of natural killer cells by host major histocompatibility complex class I molecules , 2005, Nature.

[12]  R. Vance,et al.  A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. , 2005, Blood.

[13]  F. Behm,et al.  Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors1 , 2005, The Journal of Immunology.

[14]  P. Parham,et al.  Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. , 2005, Blood.

[15]  E. Lanino,et al.  Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.

[16]  E. Romeo,et al.  Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. , 2004, International immunology.

[17]  L. Moretta,et al.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors , 2004, The EMBO journal.

[18]  R. Handgretinger,et al.  Determinants of Antileukemia Effects of Allogeneic NK Cells 1 , 2004, The Journal of Immunology.

[19]  A. Moretta,et al.  Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. , 2003, Blood.

[20]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[21]  J. Luhm,et al.  NK cells: a lesson from mismatched hematopoietic transplantation. , 2003, Trends in immunology.

[22]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[23]  Peter Parham,et al.  KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. , 2002, Annual review of immunology.

[24]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[25]  R. Biassoni,et al.  Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells , 1999, The Journal of experimental medicine.

[26]  Arne Svejgaard,et al.  Nomenclature for Factors of the HLA System, 1998 , 1999, Tissue antigens.

[27]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[28]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 1998. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[29]  Eric O Long,et al.  Regulation of immune responses through inhibitory receptors. , 1999, Annual review of immunology.

[30]  E. M. van den Berg-Loonen,et al.  A reliable and efficient high resolution typing method for HLA-C using sequence-based typing. , 1998, Tissue antigens.

[31]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[32]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[33]  Eric O Long.  Signal sequences stop killer cells. , 1998, Nature.

[34]  P Parham,et al.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. , 1997, Immunity.

[35]  P Parham,et al.  Human diversity in killer cell inhibitory receptor genes. , 1997, Immunity.

[36]  J. G. van den Tweel,et al.  A generic sequencing based typing approach for the identification of HLA-A diversity. , 1997, Human immunology.

[37]  M. Tilanus,et al.  Comparison of DRB sequence-based typing using different strategies. , 1997, Tissue antigens.

[38]  R. Biassoni,et al.  Receptors for HLA class-I molecules in human natural killer cells. , 1996, Annual review of immunology.

[39]  L. Moretta,et al.  Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells , 1995, The Journal of experimental medicine.

[40]  P. Parham,et al.  Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones , 1995, The Journal of experimental medicine.

[41]  G. Ferrara,et al.  HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Ciccone,et al.  P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities , 1993, The Journal of experimental medicine.

[43]  G. Gerna,et al.  A 6-hour microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies , 1990 .

[44]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[45]  H. Deeg,et al.  Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. , 1983, Annals of internal medicine.

[46]  M. Torres,et al.  Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.

[47]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.